Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta

Basit Öğe Kaydı
dc.authorid0000-0003-2137-7934en_US
dc.contributor.authorWranke, Anika
dc.contributor.authorHardtke, Svenja
dc.contributor.authorHeidrich, Benjamin
dc.contributor.authorDalekos, George
dc.contributor.authorYalçın, Kendal
dc.contributor.authorTabak, Fehmi
dc.contributor.authorGürel, Selim
dc.contributor.authorÇakaloglu, Yılmaz
dc.contributor.authorAkarca, Ulus S.
dc.contributor.authorLammert, Frank
dc.contributor.authorHaeussinger, Dieter
dc.contributor.authorMueller, Tobias
dc.contributor.authorWoebse, Michael
dc.contributor.authorManns, Michael P.
dc.contributor.authorİdilman, Ramazan
dc.contributor.authorCornberg, Markus
dc.contributor.authorWedemeyer, Heiner
dc.contributor.authorYurdaydın, Cihan
dc.date.accessioned2021-09-07T06:15:17Z
dc.date.available2021-09-07T06:15:17Z
dc.date.issued2020en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalı, Gastroenteroloji Bilim Dalıen_US
dc.descriptionWOS:000558543300001
dc.descriptionPMID: 32707605
dc.description.abstractHepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis. PEG-interferon alpha-2a (PEG-IFN alpha-2a) is the only effective treatment but its long-term clinical impact is unclear. The aim of this study was to investigate the long-term outcome after 48 weeks of pegylated interferon alpha-2a therapy. We performed a retrospective follow-up study of the Hep-Net-International-Delta-Hepatitis-Intervention-Study 1 (HIDIT-I trial). Patients had received 48 weeks of treatment with either PEG-IFN alpha-2a plus adefovir dipivoxil (ADV) (Group I), PEG-IFN alpha-2a alone (Group II) or adefovir dipivoxil alone (Group III). Liver-related complications were defined as liver-related death, liver transplantation, liver cancer and hepatic decompensation defined as development of Child-Pugh scores B or C or an increase in Model for End-stage Liver Disease (MELD) scores of five or more points in relation to baseline values. Patients were considered for further analysis when they were retreated with PEG-IFN alpha-2a. Follow-up data (at least 1 visit beyond post-treatment week 24) were available for 60 patients [Group I, (n = 19), Group II (n = 20), Group III (n = 21)]. Mean time of follow-up was 8.9 (1.6 - 13.4) years. 19 patients were retreated with IFN-based therapy: 42% (n = 8) in PEG-IFN alpha-2a arms and 58% (n = 11) in the adefovir only arm. Clinical complications on long-term follow-up occurred in 17 patients and were associated with nonresponse to therapy and baseline cirrhosis. The annual event-free survival rate in patients with cirrhosis vs noncirrhotic patients at year 5 and 10 was 70% vs 91% and 35% vs 76%. Long-term follow-up of a large randomized clinical trial suggests that off-treatment HDV RNA response to PEG-IFN alpha-2a treatment leads to improved clinical long-term outcome.en_US
dc.identifier.citationWranke, A., Hardtke, S., Heidrich, B., Dalekos, G., Yalçın, K., Tabak, F. ve diğerleri. (2020). Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. Journal of Viral Hepatitis, 27(12), 1359-1368.en_US
dc.identifier.doi10.1111/jvh.13366
dc.identifier.endpage1368en_US
dc.identifier.issn1352-0504
dc.identifier.issn1365-2893
dc.identifier.issue12en_US
dc.identifier.pmid32707605
dc.identifier.scopus2-s2.0-85089259771
dc.identifier.scopusqualityQ2
dc.identifier.startpage1359en_US
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.13366
dc.identifier.urihttps://hdl.handle.net/11468/7451
dc.identifier.volume27en_US
dc.identifier.wosWOS:000558543300001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorYalçın, Kendal
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal of Viral Hepatitis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic hepatitisen_US
dc.subjectClinical outcomeen_US
dc.subjectDelta virusen_US
dc.subjectEndpointen_US
dc.subjectHepatitis Den_US
dc.titleTen-year follow-up of a randomized controlled clinical trial in chronic hepatitis deltaen_US
dc.titleTen-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta.pdf
Boyut:
580.08 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu